9th AFDD Summit

With a packed schedule of scientific meetings this season, Nordic Bioscience is pleased to be participating in the 9th Antifibrotic Drug Development (AFDD) Summit, taking place November 17-19, 2025, in Boston, MA.

This highly focused event brings together leading voices in fibrosis research to accelerate the development of therapies targeting fibrotic diseases across organ systems. Nordic Bioscience will contribute to the conversation by highlighting FIB-NIT™, our non-invasive biomarker panel that quantifies both fibrogenesis and fibrolysis in real time.

Used across liver, lung, kidney, and other fibrotic conditions, FIB-NIT™ offers researchers and clinical teams a dynamic tool to better understand disease progression, enrich trial populations, and monitor treatment response. As fibrosis remains a key challenge in drug development, biomarkers like FIB-NIT™ are becoming essential to advancing targeted therapies more efficiently.

Learn more about how FIB-NIT™ is helping redefine biomarker strategies here.